According to them, their edibles are made entirely from trim concentrates that are directly mixed into the final product. So that indica edible is going to be a mix of trim from all their indicas - so sometimes a batch might be sleepy while another might just be body relaxation. That's not "medical." You never get the same effect twice! Also, direct incorporation of concentrate into edibles means a less powerful body high that lasts for less time than a real infusion. Make your edibles more bioavailable and then maybe they would last for over a handful of hours.
Dispensary Response: Hi there, thank you for your feedback. To address your comments in order: First- indica edible variation, etc. Given patient volumes and MADPH testing requirements, strain-specific edible production is not a realistically viable option. Therefore, to provide patients with a degree of selection refinement, we provision edibles in sativa, indica, hybrid, and soon, CBD varieties. The base concentrate for these batches is produced from large volume trim packages that are comprised of numerous, smaller like-variety (not strain) trim packages. Blending multiple packages like this improves batch-to-batch MIP homogeneity and should allow patients to achieve reasonably repeatable results. Additionally, a typical batch of variety specific, infusion-ready oil for NETA is quite large and may contain enough cannabinoids to produce 20,000+ 10mg edibles. This further improves batch-over homogeneity. Certainly, isolating specific cannabinoids/terpenes and infusing products with measured amounts of those would produce very repeatable results, However, the entourage effect (EE) would be nullified (think Marinol- "medical") and it is this very effect that is most therapeutic for many patients. NETA is sponsoring research on the EE and we intend to develop new products based upon those findings. Second- concentrate infusion into edibles. To be clear, NETA does not directly infuse edibles with raw concentrate. Instead, we decarboxylate said concentrates in a solution with medium chain triglycerides (MCT). MCT was developed to help treat individuals suffering from lipid absorption disorders and its incorporation in our infusion solution should significantly increase the baseline 5% bio availability for orally-consumed MIPs. Again, reliable data on this subject is scant and NETA is conducting internal research to improve the reliability of onset, duration, and terminus for MIPs. We at NETA strive to advance the science of medical marijuana on a daily basis. Given the vertical integration requirements of Massachusetts, we are proud to offer patients the breadth of therapies that we do so early in our operations. However, you can be sure that we will never rest and will continue to pursue, develop, and refine new therapies and delivery methods. Thanks